Cytomid 250mg Tablet

About

Cytomid 250mg Tablet is a non-steroidal anti-androgen (NSAA) medication specifically indicated for the treatment of prostate cancer. Its primary mechanism of action involves competitively binding to androgen receptors in target tissues, including prostate cancer cells, thereby preventing the binding and subsequent action of endogenous androgens such as testosterone and dihydrotestosterone. By blocking these hormonal signals, Cytomid effectively inhibits the growth and proliferation of androgen-sensitive prostate cancer cells, leading to disease stabilization or regression. It is frequently prescribed as part of a maximal androgen blockade (MAB) regimen, in combination with an LHRH agonist or surgical castration, to achieve a more complete suppression of androgenic stimulation. This oral formulation offers a convenient and effective option for the long-term management of hormone-dependent prostate cancer, improving patient quality of life and disease control.

Uses

• Treatment of metastatic prostate cancer
• Used in combination with LHRH agonists
• Management of advanced prostate carcinoma
• Palliative treatment for symptomatic prostate cancer

Directions For Use

Take orally as directed by your physician, usually once daily. May be taken with or without food, but maintain consistency.

Benefits

• Slows the progression of prostate cancer
• Reduces prostate-specific antigen (PSA) levels
• Helps alleviate cancer-related symptoms like bone pain
• Improves quality of life for patients
• Effective as part of combination hormonal therapy
• Convenient oral administration

Side Effects

• Hot flashes
• Gynecomastia (breast enlargement)
• Breast tenderness
• Nausea and diarrhea
• Liver enzyme elevations
• Fatigue and weakness
• Decreased libido
• Erectile dysfunction
• Skin rash
• Anemia
• Weight gain
• Fluid retention

Safety Measures

• Alcohol - Limit or avoid alcohol consumption due to the potential for increased liver strain, as this medication can cause hepatotoxicity.
• Pregnancy - Contraindicated in pregnant women due to the risk of feminization of a male fetus. Not for use by women.
• Breastfeeding - Not applicable as this medication is primarily indicated for male patients with prostate cancer.
• Liver - Use with caution in patients with liver impairment; regular monitoring of liver function tests is crucial due to the risk of hepatotoxicity.
• Kidney - Generally safe with mild to moderate renal impairment; dose adjustment may be considered in severe cases, but it is not primarily renally cleared.
• Lung - No specific lung-related safety concerns are commonly associated with this class of anti-androgen medication.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.